Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. The RaniPill capsule, the RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-101, RT-102, RT-105, RT-110 and RT-111. Its RT-101 is an Octreotide for the treatment of NETs and acromegaly. It manufactures and assembles RaniPill capsules at its facility in San Jose, California.
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
|Date||Event description||Earnings per|
|May 10, 2023||Q1 2023 Earnings Release||-$0.33||-$0.69 to -$0.33||-$0.29|
|March 22, 2023||Q4 2022 Earnings Release||-$0.35||-$0.54 to -$0.17||-$0.27|
|November 10, 2022||Q3 2022 Earnings Release||-$0.33||-$0.73 to -$0.31||-$0.12|
|August 10, 2022||Q2 2022 Earnings Release||-$0.31||-$1.11 to -$0.28||-$0.12|
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.